Researchers at The Royal Marsden and The Institute of Cancer Research have developed a saliva test that could be a better way to identify men at high risk of prostate cancer than the prostate-specific antigen (PSA) test.

Findings from the BARCODE 1 study, presented at ASCO 2024, calculated the prostate cancer polygenic risk score (PRS) of patients recruited. Of these, 40% of the men with a high PRS score were diagnosed with prostate cancer, a significant increase from those identified by the PSA test. The new test also detected that 55% of the cancers in the study were aggressive, improving on the 36% in detected by the PSA test.

The PRSs were based on 130 genetic variations shown to be linked with prostate cancer.

The must-attend session chaired by Darren Hargrave (University College London/Great Ormond Street Hospital) will showcase international perspectives, expertise and insights on some of the most prominent issues in the field.

Join Juanita Lopez (The Royal Marsden) to explore disruptive clinical trial design for genomically complex brain tumours. Nader Sanai (Barrow Neurological Institute) will share insights into pharmacokinetic/ pharmacodynamic-driven clinical trials for brain tumours.

Follow our social media channels with #CRUKBrain24 for more updates.